Sirona Biochem (Seite 3104)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 24.05.24 19:03:38 von
neuester Beitrag 24.05.24 19:03:38 von
Beiträge: 31.056
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 5
Gesamt: 5.406.773
Gesamt: 5.406.773
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0430
EUR
+6,17 %
+0,0025 EUR
Letzter Kurs 24.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6220 | +108,03 | |
| 55,50 | +36,03 | |
| 1,7870 | +28,56 | |
| 1,0300 | +27,16 | |
| 1,0500 | +23,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -31,17 | |
| 2,6200 | -43,04 | |
| 0,7900 | -45,89 | |
| 1,0200 | -53,64 | |
| 4,1200 | -66,17 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 45.086.467 von Jon_Schnee am 21.07.13 15:40:24Sirona Biochem’s Skin Lightening nicht nur Sicher und Effizient. Sondern auch noch nebenbei "Anti Age" Wirkung. Wir warten hier immer noch auf einen Partner.
Sommer Sonne Sonnenschein - die Asiaten werden im Gegensatz zu Europärer nicht gerne braun. Skin Ligtening (Creme) ist ein riesiger Markt.
hier ein paar Bilder:
https://www.google.ch/search?q=Skin+Lightening&tbm=isch&tbo=…
Sommer Sonne Sonnenschein - die Asiaten werden im Gegensatz zu Europärer nicht gerne braun. Skin Ligtening (Creme) ist ein riesiger Markt.
hier ein paar Bilder:
https://www.google.ch/search?q=Skin+Lightening&tbm=isch&tbo=…
Eine Woche Ferien in Schwarzwald 
war klasse, super schöne Landschaften und malerische Städtchen und Dörfer und die Dorffester haben es in sich .)
Mehr als eine Alternative zu Spanien, Italien etc...
NEWS:
Sirona Biochem’s Skin Lightening Compounds Demonstrate Significant Antioxidant Properties
Vancouver, British Columbia – July 15, 2013 – Sirona Biochem Corp. (TSX-V: SBM), announced today its skin lightening compounds have shown to have significant antioxidant activity. The study was performed by Biogalenys, a France based company (www.biogalenys.com). Antioxidant testing measures the ability of a compound to inhibit the oxidation of other molecules. Insufficient levels of antioxidants can cause oxidative stress, which produces free radicals that can be toxic to parts of cells, potentially causing diseases. Antioxidants are being investigated for their abilities to prevent diseases.
In the study, the antioxidant potential of compounds TFC-849 and TFC-723 was evaluated using a standard DPPH assay, and their efficiency factors were determined. The antioxidant activity of the compounds was evaluated by determining resultant levels of IC50, a molar ratio showing the concentration of the antioxidant leading to 50% reduction of the initial DPPH concentration. Both of the company’s compounds were proven to have free radical scavenging activity.
While both compounds were qualified as antioxidants, TFC-723 showed to be two times more efficient than both natural alpha and beta arbutin. Moreover, the free radical scavenging activity of TFC-723 was slightly higher than that of Ascorbic Acid Glucoside, commonly used in cosmetic products for this purpose.
“In scientific research, our compounds continue to demonstrate superior efficacy and safety and now show the added benefit of proven antioxidant properties,” said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “This is another exciting breakthrough and again raises the bar of quality in a multi-billion dollar industry,” he added.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: 604.282.6065
Email: aissa@sironabiochem.com
war klasse, super schöne Landschaften und malerische Städtchen und Dörfer und die Dorffester haben es in sich .)Mehr als eine Alternative zu Spanien, Italien etc...
NEWS:
Sirona Biochem’s Skin Lightening Compounds Demonstrate Significant Antioxidant Properties
Vancouver, British Columbia – July 15, 2013 – Sirona Biochem Corp. (TSX-V: SBM), announced today its skin lightening compounds have shown to have significant antioxidant activity. The study was performed by Biogalenys, a France based company (www.biogalenys.com). Antioxidant testing measures the ability of a compound to inhibit the oxidation of other molecules. Insufficient levels of antioxidants can cause oxidative stress, which produces free radicals that can be toxic to parts of cells, potentially causing diseases. Antioxidants are being investigated for their abilities to prevent diseases.
In the study, the antioxidant potential of compounds TFC-849 and TFC-723 was evaluated using a standard DPPH assay, and their efficiency factors were determined. The antioxidant activity of the compounds was evaluated by determining resultant levels of IC50, a molar ratio showing the concentration of the antioxidant leading to 50% reduction of the initial DPPH concentration. Both of the company’s compounds were proven to have free radical scavenging activity.
While both compounds were qualified as antioxidants, TFC-723 showed to be two times more efficient than both natural alpha and beta arbutin. Moreover, the free radical scavenging activity of TFC-723 was slightly higher than that of Ascorbic Acid Glucoside, commonly used in cosmetic products for this purpose.
“In scientific research, our compounds continue to demonstrate superior efficacy and safety and now show the added benefit of proven antioxidant properties,” said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “This is another exciting breakthrough and again raises the bar of quality in a multi-billion dollar industry,” he added.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: 604.282.6065
Email: aissa@sironabiochem.com
Sirona Biochem Announces LOI for Collaboration with Biogalenys
http://www.sironabiochem.com/sirona-biochem-announces-loi-fo…
Vancouver, British Columbia
– July 2, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB) is pleased to announce the signing of a Letter of Intent (LOI) for a collaboration with Biogalenys. The goal of the collaboration is to study Sirona Biochem’s patented glycoprotein (cell preservation) technology and to develop preclinical data supporting multiple targeted applications.
Using its proprietary chemistry technique, Sirona Biochem has developed and patented a cell preservation technology that (early tests have shown) protects human fibroblast cells from damage in stressed environments. Potential applications of this technology include, but are not limited to: anti-aging cream, sunscreen / UV protection, wound care, reduced scarring, frostbite protection, stem cell preservation, beta islet cell preservation, platelet and red blood cell preservation, and increased preservation times for tissue explants and organ transplantation.
The proposed 3 year collaboration will focus on first studying the application of Sirona Biochem’s cell preservation technology for use as a cosmetic anti-aging active ingredient and as a preservative adjuvant for tissue explants.
“We are excited to be creating a second project partnership with Biogalenys,” said Neil Belenkie, CEO of Sirona Biochem. “We look forward to continuing the success that our companies achieved on our skin lightening project; applying our shared expertise in the study and development of our new cell preservation technology”.
“We are extremely happy to continue our collaboration with Sirona Biochem and to work in partnership on their scientific innovations in the future, which will allow the simultaneous development of our two companies on an international level,” said Pascal Svinareff, CEO
http://www.sironabiochem.com/sirona-biochem-announces-loi-fo…
Vancouver, British Columbia
– July 2, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB) is pleased to announce the signing of a Letter of Intent (LOI) for a collaboration with Biogalenys. The goal of the collaboration is to study Sirona Biochem’s patented glycoprotein (cell preservation) technology and to develop preclinical data supporting multiple targeted applications.
Using its proprietary chemistry technique, Sirona Biochem has developed and patented a cell preservation technology that (early tests have shown) protects human fibroblast cells from damage in stressed environments. Potential applications of this technology include, but are not limited to: anti-aging cream, sunscreen / UV protection, wound care, reduced scarring, frostbite protection, stem cell preservation, beta islet cell preservation, platelet and red blood cell preservation, and increased preservation times for tissue explants and organ transplantation.
The proposed 3 year collaboration will focus on first studying the application of Sirona Biochem’s cell preservation technology for use as a cosmetic anti-aging active ingredient and as a preservative adjuvant for tissue explants.
“We are excited to be creating a second project partnership with Biogalenys,” said Neil Belenkie, CEO of Sirona Biochem. “We look forward to continuing the success that our companies achieved on our skin lightening project; applying our shared expertise in the study and development of our new cell preservation technology”.
“We are extremely happy to continue our collaboration with Sirona Biochem and to work in partnership on their scientific innovations in the future, which will allow the simultaneous development of our two companies on an international level,” said Pascal Svinareff, CEO
Drug R&D Cosmeceuticals: Sirona Biochem Pursues Dual Strategy
March 20, 2013 at 09:28:07 EST by The Bottom Line Report
http://healthcare.vantagewire.ca/articles/drug-rd-cosmeceuti…
March 20, 2013 at 09:28:07 EST by The Bottom Line Report
http://healthcare.vantagewire.ca/articles/drug-rd-cosmeceuti…
Sirona Biochem moving ahead with ambitious plans after filling its financial coffers
15th May 2013, 3:00 pm by Anwar Ali
http://www.proactiveinvestors.com/companies/news/43789/siron…
15th May 2013, 3:00 pm by Anwar Ali
http://www.proactiveinvestors.com/companies/news/43789/siron…
Trading Spotlight
Gedanken zu:
Sirona Biochem Announces LOI for Collaboration with VitamFero
http://www.sironabiochem.com/sirona-biochem-announces-loi-fo…
VitamFero schloss VorAgreement mit Merial ab. Merial kann innerhalb von 12 Monaten dem Agreement zustimmen (Merial gehört zu Sanofi; also ein Multi in der Pharmabranche)
VitamFero signs agreement with Merial to develop new production animal
antiparasitic vaccines.
http://www.vitamfero.com/public/communiques/EN_13_01_21_Vita…
VitamFero und Sirona Biochem haben einen LOI, Merial und VitamFero auch. Sollte hier alles gut gehen, spielt Sirona bei Tierimpfungen auf ein Schlag mit den grossen mit.
Das schöne bei Sirona Biochem ist dass sie viele Eisen im Feuer haben
Sirona Biochem Announces LOI for Collaboration with VitamFero
http://www.sironabiochem.com/sirona-biochem-announces-loi-fo…
VitamFero schloss VorAgreement mit Merial ab. Merial kann innerhalb von 12 Monaten dem Agreement zustimmen (Merial gehört zu Sanofi; also ein Multi in der Pharmabranche)
VitamFero signs agreement with Merial to develop new production animal
antiparasitic vaccines.
http://www.vitamfero.com/public/communiques/EN_13_01_21_Vita…
VitamFero und Sirona Biochem haben einen LOI, Merial und VitamFero auch. Sollte hier alles gut gehen, spielt Sirona bei Tierimpfungen auf ein Schlag mit den grossen mit.
Das schöne bei Sirona Biochem ist dass sie viele Eisen im Feuer haben
Acquisition of Shares of Sirona Biochem Corp.
http://www.finanznachrichten.de/nachrichten-2013-06/27264818…
Pathfinder Asset Management Limited
http://www.paml.ca/
...
As a result of the Acquisition, Pathfinder currently exercises control or direction over approximately 6.13% of the current total number of issued and outstanding Common Shares. In the event that all such Warrants are exercised, Pathfinder would exercise control or direction over a total of 12,000,000 Common Shares representing 11.56% of the current issued and outstanding Common Shares (assuming that Sirona issues no other securities).
The Acquisition was made by Pathfinder for investment purposes on behalf of client accounts over which it has discretionary trading authority. Pathfinder may, in the future, acquire additional securities of Sirona for investment purposes on its own behalf or on behalf of client accounts over which it has discretionary trading authority.
...
http://www.finanznachrichten.de/nachrichten-2013-06/27264818…
Pathfinder Asset Management Limited
http://www.paml.ca/
...
As a result of the Acquisition, Pathfinder currently exercises control or direction over approximately 6.13% of the current total number of issued and outstanding Common Shares. In the event that all such Warrants are exercised, Pathfinder would exercise control or direction over a total of 12,000,000 Common Shares representing 11.56% of the current issued and outstanding Common Shares (assuming that Sirona issues no other securities).
The Acquisition was made by Pathfinder for investment purposes on behalf of client accounts over which it has discretionary trading authority. Pathfinder may, in the future, acquire additional securities of Sirona for investment purposes on its own behalf or on behalf of client accounts over which it has discretionary trading authority.
...
2 LOI innerhalb eines Monat, Intresse ist also durchaus da.
Die grossen Deals kommen noch.
http://www.sironabiochem.com/
Sirona Biochem Announces LOI for Collaboration with VitamFero
25 Jun 2013
Sirona Biochem Announces LOI for Collaboration with Cincinnati Children’s Hospital Medical Center
29 May 2013
Die grossen Deals kommen noch.
http://www.sironabiochem.com/
Sirona Biochem Announces LOI for Collaboration with VitamFero
25 Jun 2013
Sirona Biochem Announces LOI for Collaboration with Cincinnati Children’s Hospital Medical Center
29 May 2013
NBT - SIRONA - 1+2 (SBM.V) Tobin Smith, Neil Belenkie
http://nbtequitiesresearch.com/david/Marcum_MicroCap_Confere…
http://nbtequitiesresearch.com/david/Marcum_MicroCap_Confere…
!
Dieser Beitrag wurde von a.mueller moderiert. Grund: Spam, Werbung
Durchsuchen
Sirona Biochem
